FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094840930> ?p ?o ?g. }

• W3094840930 endingPage "31" @default.
• W3094840930 startingPage "30" @default.
• W3094840930 abstract "Background: Rabbit anti-thymocyte globulin (rATG) is used in allogeneic hematopoietic cell transplantation (alloHCT) to prevent graft versus host-disease (GVHD) and graft rejection. In the T-cell replete setting, post-HCT rATG exposure is variable with high exposures resulting in delayed CD4+immune reconstitution (CD4+IR) and higher mortality. The goal of this study was to estimate the rATG exposure in pediatric and adult recipients of ex vivo T-cell depleted CD34+ selected alloHCT and correlate it with outcomes to determine the optimal exposure. Methods: We performed a retrospective analysis of patients who underwent their first myeloablative-conditioned ex vivo CD34+ selected alloHCT between 2008 and 2018. Post-HCT rATG exposure was estimated as area under the curve (AUC) (mg*d/L) using a validated population pharmacokinetic (PK) model (Admiraal et al.,Lancet Hematology 2017). Outcomes of interest were CD4+IR, defined as CD4+&gt;50/uL at two consecutive measures within 100 days of HCT, non-relapse mortality (NRM), overall survival (OS), GVHD, and relapse. We evaluated the association between post-HCT rATG exposures and CD4+IR using a smoothed effect to define the optimal post-HCT rATG exposure. We subsequently analyzed outcomes in 3 post-HCT rATG exposure groups, &lt;30 mg*d/L, 30-55 mg*d/L, and &gt;=55 mg*d/L. Cox proportional hazard models and multi-state competing risk models were used for analyses. Results: Of 554 patients included, 239 (43%) were female, median age at HCT was 49 (range 0.2 to 73) years and 425 (76.7%) received matched donor transplant, while 129 (23.3%) patients received mismatched donor HCT. In this cohort of patients, 515 (93%) underwent alloHCT for hematologic malignancies - leukemia: 356 (64.3%), myelodysplastic syndrome: 122 (22%), and other hematological malignancies: 37 (6.7%) while 39 (7%) underwent alloHCT for non-malignant indications. Total Body Irradiation based conditioning regimen was administered in 177 (32%) patients. Among all 554 patients, 540 (97%) attained engraftment. Median post-HCT rATG exposure was 47mg*d/L (range 0 - 101 mg*d/L). A decreasing post-HCT AUC (optimum &lt;30 mg*d/L) was associated with higher probability of CD4+IR (p&lt; 0.0001, Figure 1a); lower NRM (p=0.03, Figure 1b) and improved OS (p=0.05, Figure 1c). Patients who attained CD4+IR earlier had lower rates of NRM (p&lt;0.0001, Figure 1d). On further assessing rATG exposure post allo-HCT by three cut -off levels (&lt;30mg*d/L, 30-55 mg*d/L and &gt;=55 mg*d/L), time to CD4+IR varied depending on the ATG exposure (Figure 1e). In multivariable cox models, post-HCT rATG exposure &gt;=55 mg*d/L was associated with an increased risk of NRM as compared to the lower exposure of &lt;30 mg*d/L (HR: 4.11, CI: 1.52, 11.2, Figure 1f), and inferior OS (HR: 2.03, CI: 1.03,4.00, Figure 1g). In addition, post-HCT rATG exposure &gt;=55 mg*d/L was associated with a higher risk of acute GVHD (HR: 2.28, CI: 1.01, 5.16, Figure 1h). In patients with hematologic malignancies, post-HCT rATG exposure was not associated with relapse (HR: 0.73, CI: 0.31,1.7). In the entire cohort of 554 patients, 9 (1.6%) patients had graft rejection: 1 primary rejection in the post-HCT ATG exposure &lt;30mg*d/L group, 6 secondary rejections in the post-HCT ATG exposure of 30-55 mg*d/L group and 2 secondary rejections in the post-HCT ATG exposure &gt;=55mg*d/L group. Among all patients, 204 (37%) died secondary to reasons such as relapse of disease: 73 (36%), infection: 51 (25%), GVHD: 40 (20%), toxicity/organ failure: 29 (14%) and other causes: 11 (5%). Conclusions: In a large cohort of patients who underwent ex vivo CD34+ selected alloHCT, higher post-HCT rATG exposure led to higher NRM, a paradoxical increase in GVHD, and lower OS driven by poorer CD4+ IR. The increased rates of GVHD with higher post-HCT exposure may be related to increased infections in these cohorts, though this needs to be explored further. Individualizing rATG dosing by PK targeting to a low post-HCT rATG exposure may improve outcomes. We intend to validate these results in a forthcoming prospective clinical trial. Figure 1 Disclosures Scordo: McKinsey & Company: Consultancy; Angiocrine Bioscience, Inc.: Consultancy, Research Funding; Omeros Corporation: Consultancy; Kite - A Gilead Company: Other: Ad-hoc advisory board. Curran:Celgene: Research Funding; Novartis: Consultancy, Research Funding; Mesoblast: Consultancy. Kernan:Amgen: Current equity holder in publicly-traded company; Merck: Current equity holder in publicly-traded company; Johnson and Johnson: Current equity holder in publicly-traded company; Pfizer: Current equity holder in publicly-traded company. O'Reilly:Atara Biotherapeutics: Consultancy, Patents & Royalties: EBV-specific T-cell bank, Research Funding. Prockop:Mesoblast, Inc,: Consultancy, Honoraria, Research Funding; Atara: Research Funding; Jasper: Research Funding. Scaradavou:Excellthera: Membership on an entity's Board of Directors or advisory committees. Shah:Amgen Inc.: Research Funding; Janssen: Research Funding. Giralt:OMEROS: Consultancy, Honoraria; NOVARTIS: Consultancy, Honoraria, Research Funding; KITE: Consultancy; MILTENYI: Consultancy, Research Funding; ACTINUUM: Consultancy, Research Funding; TAKEDA: Research Funding; CELGENE: Consultancy, Honoraria, Research Funding; JAZZ: Consultancy, Honoraria; AMGEN: Consultancy, Research Funding. Perales:Medigene: Membership on an entity's Board of Directors or advisory committees, Other; NexImmune: Membership on an entity's Board of Directors or advisory committees; Omeros: Honoraria, Membership on an entity's Board of Directors or advisory committees; Nektar Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees, Other; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Merck: Consultancy, Honoraria; Celgene: Honoraria; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Miltenyi Biotec: Research Funding; Kite/Gilead: Honoraria, Research Funding; Incyte Corporation: Honoraria, Research Funding; MolMed: Membership on an entity's Board of Directors or advisory committees; Cidara Therapeutics: Other; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bellicum: Honoraria, Membership on an entity's Board of Directors or advisory committees. Boelens:Bluebird Bio: Consultancy; Advanced Clinical: Consultancy; Race Oncology: Consultancy; Bluerock: Consultancy; Omeros: Consultancy; Avrobio: Consultancy; Takeda: Consultancy." @default.
• W3094840930 created "2020-11-09" @default.
• W3094840930 creator A5001390394 @default.
• W3094840930 creator A5016160764 @default.
• W3094840930 creator A5021595775 @default.
• W3094840930 creator A5026131694 @default.
• W3094840930 creator A5027007983 @default.
• W3094840930 creator A5031248362 @default.
• W3094840930 creator A5031349996 @default.
• W3094840930 creator A5031390617 @default.
• W3094840930 creator A5038938737 @default.
• W3094840930 creator A5044552886 @default.
• W3094840930 creator A5047384277 @default.
• W3094840930 creator A5050407540 @default.
• W3094840930 creator A5052956899 @default.
• W3094840930 creator A5055001531 @default.
• W3094840930 creator A5056115129 @default.
• W3094840930 creator A5058476408 @default.
• W3094840930 creator A5058746837 @default.
• W3094840930 creator A5059247439 @default.
• W3094840930 creator A5064076262 @default.
• W3094840930 creator A5067712388 @default.
• W3094840930 creator A5070096873 @default.
• W3094840930 creator A5079103223 @default.
• W3094840930 creator A5082333371 @default.
• W3094840930 creator A5085550690 @default.
• W3094840930 creator A5085595407 @default.
• W3094840930 date "2020-11-05" @default.
• W3094840930 modified "2023-10-17" @default.
• W3094840930 title "Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults" @default.
• W3094840930 doi "https://doi.org/10.1182/blood-2020-136341" @default.
• W3094840930 hasPublicationYear "2020" @default.
• W3094840930 type Work @default.
• W3094840930 sameAs 3094840930 @default.
• W3094840930 citedByCount "0" @default.
• W3094840930 crossrefType "journal-article" @default.
• W3094840930 hasAuthorship W3094840930A5001390394 @default.
• W3094840930 hasAuthorship W3094840930A5016160764 @default.
• W3094840930 hasAuthorship W3094840930A5021595775 @default.
• W3094840930 hasAuthorship W3094840930A5026131694 @default.
• W3094840930 hasAuthorship W3094840930A5027007983 @default.
• W3094840930 hasAuthorship W3094840930A5031248362 @default.
• W3094840930 hasAuthorship W3094840930A5031349996 @default.
• W3094840930 hasAuthorship W3094840930A5031390617 @default.
• W3094840930 hasAuthorship W3094840930A5038938737 @default.
• W3094840930 hasAuthorship W3094840930A5044552886 @default.
• W3094840930 hasAuthorship W3094840930A5047384277 @default.
• W3094840930 hasAuthorship W3094840930A5050407540 @default.
• W3094840930 hasAuthorship W3094840930A5052956899 @default.
• W3094840930 hasAuthorship W3094840930A5055001531 @default.
• W3094840930 hasAuthorship W3094840930A5056115129 @default.
• W3094840930 hasAuthorship W3094840930A5058476408 @default.
• W3094840930 hasAuthorship W3094840930A5058746837 @default.
• W3094840930 hasAuthorship W3094840930A5059247439 @default.
• W3094840930 hasAuthorship W3094840930A5064076262 @default.
• W3094840930 hasAuthorship W3094840930A5067712388 @default.
• W3094840930 hasAuthorship W3094840930A5070096873 @default.
• W3094840930 hasAuthorship W3094840930A5079103223 @default.
• W3094840930 hasAuthorship W3094840930A5082333371 @default.
• W3094840930 hasAuthorship W3094840930A5085550690 @default.
• W3094840930 hasAuthorship W3094840930A5085595407 @default.
• W3094840930 hasBestOaLocation W30948409301 @default.
• W3094840930 hasConcept C126322002 @default.
• W3094840930 hasConcept C194409129 @default.
• W3094840930 hasConcept C203014093 @default.
• W3094840930 hasConcept C207103383 @default.
• W3094840930 hasConcept C2777408962 @default.
• W3094840930 hasConcept C2779972918 @default.
• W3094840930 hasConcept C2780882860 @default.
• W3094840930 hasConcept C2908647359 @default.
• W3094840930 hasConcept C2911091166 @default.
• W3094840930 hasConcept C44249647 @default.
• W3094840930 hasConcept C50382708 @default.
• W3094840930 hasConcept C71924100 @default.
• W3094840930 hasConcept C90924648 @default.
• W3094840930 hasConcept C99454951 @default.
• W3094840930 hasConceptScore W3094840930C126322002 @default.
• W3094840930 hasConceptScore W3094840930C194409129 @default.
• W3094840930 hasConceptScore W3094840930C203014093 @default.
• W3094840930 hasConceptScore W3094840930C207103383 @default.
• W3094840930 hasConceptScore W3094840930C2777408962 @default.
• W3094840930 hasConceptScore W3094840930C2779972918 @default.
• W3094840930 hasConceptScore W3094840930C2780882860 @default.
• W3094840930 hasConceptScore W3094840930C2908647359 @default.
• W3094840930 hasConceptScore W3094840930C2911091166 @default.
• W3094840930 hasConceptScore W3094840930C44249647 @default.
• W3094840930 hasConceptScore W3094840930C50382708 @default.
• W3094840930 hasConceptScore W3094840930C71924100 @default.
• W3094840930 hasConceptScore W3094840930C90924648 @default.
• W3094840930 hasConceptScore W3094840930C99454951 @default.
• W3094840930 hasIssue "Supplement 1" @default.
• W3094840930 hasLocation W30948409301 @default.
• W3094840930 hasOpenAccess W3094840930 @default.
• W3094840930 hasPrimaryLocation W30948409301 @default.
• W3094840930 hasRelatedWork W2095493168 @default.
• W3094840930 hasRelatedWork W2338540107 @default.
• W3094840930 hasRelatedWork W2503366837 @default.
• W3094840930 hasRelatedWork W2538699508 @default.

• next